Consistent Revenue and EBITDA Growth
Bausch Health marked its seventh consecutive quarter of revenue and adjusted EBITDA growth, with a 4% revenue increase on a reported basis and 7% on an organic basis for Q4 2024. Full-year revenue increased by 5% on a reported basis and 6% on an organic basis.
Strong Cash Flow Generation
The company generated approximately $1.3 billion in adjusted operating cash flow for the full year, which exceeded guidance, driven by operational performance, low cash taxes, and favorable timing of outflows.
Solta Medical Segment Performance
Solta revenue increased by 34% in Q4, primarily driven by volume and strong performance in South Korea and China. The segment is well-positioned for sustained growth.
Xifaxan Revenue Growth
Xifaxan delivered a 16% revenue growth in Q4, with solid volume growth across all channels, marking the fourth consecutive quarter of growth.
International Business Growth
Canada achieved double-digit growth in promoted brands, and EMEA business achieved its eighth consecutive quarter of organic growth.